

The evaluation of bulbar dysfunction in amyotrophic lateral sclerosis: survey of clinical practice patterns in the United States

Emily K. Plowman, Lauren C. Tabor, James Wymer & Gary Pattee

To cite this article: Emily K. Plowman, Lauren C. Tabor, James Wymer & Gary Pattee (2017) The evaluation of bulbar dysfunction in amyotrophic lateral sclerosis: survey of clinical practice patterns in the United States, *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, 18:5-6, 351-357, DOI: [10.1080/21678421.2017.1313868](https://doi.org/10.1080/21678421.2017.1313868)

To link to this article: <https://doi.org/10.1080/21678421.2017.1313868>



Published online: 20 Apr 2017.



Submit your article to this journal [↗](#)



Article views: 210



View related articles [↗](#)



View Crossmark data [↗](#)



Citing articles: 2 View citing articles [↗](#)



RESEARCH ARTICLE

The evaluation of bulbar dysfunction in amyotrophic lateral sclerosis: survey of clinical practice patterns in the United States

EMILY K. PLOWMAN^{1,2,3,4}, LAUREN C. TABOR^{1,4}, JAMES WYMER³ & GARY PATTEE⁵

¹Swallowing Systems Core, University of Florida, Gainesville, FL, USA, ²Department of Speech, Language and Hearing Science, University of Florida, Gainesville, FL, USA, ³Department of Neurology, University of Florida, Gainesville, FL, USA, ⁴Department of Physical Therapy, University of Florida, Gainesville, FL, USA, and ⁵Department of Neurology, Neurology Associates, University of Nebraska, Lincoln, NE, USA

Abstract

Objective: Speech and swallowing impairments are highly prevalent in individuals with amyotrophic lateral sclerosis (ALS) and contribute to reduced quality of life, malnutrition, aspiration, pneumonia and death. Established practice parameters for bulbar dysfunction in ALS do not currently exist. The aim of this study was to identify current practice patterns for the evaluation of speech and swallowing function within participating Northeast ALS clinics in the United States. **Methods and results:** A 15-item survey was emailed to all registered NEALS centres. Thirty-eight sites completed the survey. The majority (92%) offered Speech-Language Pathology, augmentative and alternative communication (71%), and dietician (92%) health care services. The ALS Functional Rating Scale-Revised and body weight represented the only parameters routinely collected in greater than 90% of responding sites. Referral for modified barium swallow study was routinely utilised in only 27% of sites and the use of percutaneous gastrostomy tubes in ALS patient care was found to vary considerably. **Conclusions:** This survey reveals significant variability and inconsistency in the management of bulbar dysfunction in ALS across NEALS sites. We conclude that a great need exists for the development of bulbar practice guidelines in ALS clinical care to accurately detect and monitor bulbar dysfunction.

Keywords: Amyotrophic lateral sclerosis; bulbar; practice patterns; speech; swallow; survey

Introduction

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease resulting in progressive weakness of voluntary muscles. Motor denervation of the bulbar musculature leads to progressive speech (dysarthria) and swallowing (dysphagia) impairment in ~85% of patients (1,2). Loss of functional oral intake contributes to social isolation and diminished quality of life (3,4) and the potential loss of speech has been rated by ALS patients as the worst aspect of the disease (5). In addition to these psychosocial sequelae, bulbar dysfunction contributes to malnutrition, dehydration, tracheal aspiration and pneumonia (2,6–8), which together account for 26% of ALS mortality (9) and increases the risk of death 7.7-fold in this patient population (6). These factors underscore the critical need for early detection and accurate monitoring of bulbar dysfunction to ensure optimal nutritional intake,

communication abilities, pulmonary function and quality of life in individuals with ALS (10,11).

Although limited advances have been made in the management of individuals with ALS, care at specialised multidisciplinary clinics has been shown to improve quality of life, reduce hospitalisation rates and extend survival (12–15) and constitutes current practice recommendations of the American Academy of Neurology (16) and European Federation of Neurological Societies (17). While this comprehensive multidisciplinary model allows great breadth of care (with up to eight different health care consultations), it requires that individual clinicians perform abbreviated evaluations and underscores the need for quick, efficient, and accurate screening tools to detect speech and swallowing impairments in ALS (10,11).

Internationally accepted practice guidelines for the evaluation of bulbar function in ALS are currently lacking and little is known regarding the

routine, clinical utilisation of assessment protocols. Furthermore, referral patterns for instrumental swallowing examination or percutaneous gastrostomy (PEG) tube placement, including whom within the health care team is administrating these protocols is largely unknown. As an initial step towards the establishment of best practice guidelines, we surveyed current practice patterns throughout Northeastern ALS (NEALS) centres within the United States regarding the assessment and monitoring of speech and swallowing function in patients with ALS.

Methods

An internet-based survey was developed and administered to members of NEALS who currently work with individuals with ALS across various clinical settings including private neurology groups, hospitals, outpatient rehabilitation centres and University clinics. The final survey was prepared on Survey Monkey's online interface (www.surveymonkey.com). Email invitations with survey links were sent using Survey Monkey's Email Invitation Collector system and remained open for a 30-d-period during June 2015. No compensation was offered to the respondents. The complete survey is provided in the Appendix and consists of 15 questions indexing respondents' clinic patient population demographics (Q1, Q2); routinely administered tests and clinical parameters (Q3); healthcare professional services offered (Q4–Q9); and referral preferences for procedures related to nutrition and swallowing function (Q9–Q15). Survey questions included: multiple-choice (12 items), binary yes/no (three items) and short answer (one item) questions. The survey was designed to be low burden (i.e. short, electronic submission) to encourage respondent participation and completion of all survey items. Descriptive summary statistics were applied and included: frequency counts, mean, mode, standard

deviation and range to profile current practice patterns in responding sites.

Results

Survey response demographics

Thirty-eight surveys were submitted electronically between 1 June and 22 June 2015. Respondents included neurologists (63.1%, $n = 24$), nurse practitioners (13.2%, $n = 5$), and speech-language pathologists (SLPs) (10.5%, $n = 4$). Five respondents (13.2%) reported anonymously on behalf of their ALS clinic. All respondents currently work with ALS patients across a variety of clinical settings, with most (66%) working in a university medical setting (see Table 1 for full clinical setting data).

ALS patient characteristics

Table 2 presents data for the number and reported degree of bulbar involvement in ALS patients seen at clinical sites completing this survey. Twenty sites (52.6%) report seeing greater than 21 ALS patients per month (new and returning patients), with the most common response item being '11–20 patients' (32.2% of responders). Seventy-four percent ($n = 28$) of respondents indicated that bulbar symptoms are present in 15–34% of their patients.

Routinely collected clinical parameters

Question 3 prompted clinicians to select clinical parameters routinely reported on ALS patients during their clinical visits (permitted to select as many clinical parameters from the 10 available options, see Appendix, Question 3). The average number of clinical parameters reported by respondents was 5.5 (SD: 1.7, range 1–8). Figure 1 summarises the relative percentage of sites routinely reporting each of the 10 bulbar-related clinical parameters surveyed. No single clinical parameter was routinely reported across all 38 sites. The ALS Functional Rating Scale-Revised (ALSFRS-R) (18) represented the most commonly reported parameter with 97.4% ($n = 37$) of clinical sites reporting its routine use. Other widely utilised clinical outcomes included body weight (94.7%, $n = 36$), forced vital capacity (FVC; 89.5%, $n = 34$), and body mass index (BMI; 63.2%, $n = 24$). The least utilised clinical indices of the 10 available options included: speaking rate (18.4%, $n = 7$), the Sentence

Table 1. Demographic information of clinical sites completing the survey.

| Clinical Setting | % (n) |
|-------------------------|------------|
| University ALS Clinic | 65.8% (25) |
| Private Neurology Group | 7.9% (3) |
| Hospital | 5.3% (2) |
| Rehabilitation Centre | 2.6% (1) |
| Veterans Affairs | 2.6% (1) |
| Unknown | 2.6% (1) |

Table 2. ALS patient characteristics of responding clinical sites.

| | | | | | |
|--|----------------|----------------|---------------|---------------|--|
| 1. How many new and return ALS patients are seen each month? | | | | | |
| <10 | 11–20 | 21–30 | 31–40 | >40 | |
| 13.2% (n = 5) | 34.2% (n = 13) | 15.8% (n = 6) | 18.4% (n = 7) | 18.2% (n = 7) | |
| 2. What percentage of patients present with bulbar symptoms? | | | | | |
| <15% | 15–24% | 25–34% | 31–40% | >40% | |
| 7.9% (n = 3) | 44.7% (n = 13) | 28.9% (n = 11) | 10.3% (n = 4) | 7.9% (n = 3) | |

Clinical parameters routinely reported:

"Which of the following are routinely collected at each clinic visit"




Figure 1. Questions 3 group data indexing clinical parameters routinely collected in ALS clinical parameters routinely collected in ALS clinics. Data represent percentage of respondentage who report using specific parameter.

Frequency of MBS Referral:

"What Percentage of your patients do you refer for MBS"




Figure 2. Question 9 group data for the reported percentage of ALS patients who are referred for a modified barium swallows (MBS) exam (numbers indicate the number of responses for each choice option).

Intelligibility Test (SIT; 18.4%, $n = 7$), maximum expiratory pressure (MEP; 28.9%, $n = 11$), and a calorie count (36.8%, $n = 14$).

Health care services offered (Questions 4–8)

Of sites surveyed, 92.1% ($n = 35$) reported the provision of an SLP in their ALS clinic. Of the three sites which did not offer SLP services, two represented university clinics and one was an anonymous respondent. SLPs were reported to see all patients in 63.4% ($n = 23$) of sites; per physician referral in 30.6% ($n = 11$) of sites; and only in ALS patients with bulbar symptoms in 5.6% ($n = 2$) of clinics. An Augmentative and Alternative Communication (AAC) expert was present in 74.4% ($n = 28$) of responding clinics, who provided AAC evaluations (71.0% of sites), communication

Table 3. Summary of Question 10 short answer responses ($n = 18$).

Rationale for not performing a Modified Barium Swallowing Study

- Physician preference only.
- SLP and physician clinical assessments are sufficient.
- MBS poses the risk for barium aspiration.
- The disease progresses too quickly for MBS to be useful.
- It does not add useful information.
- Clients often seen for an MBS during differential diagnosis prior to being referred to our clinic.
- We refer only a small number of patients who want to remain eating (and defer PEG tube placement) to enhance and educate on safe swallowing techniques.
- No access to MBS on-site.
- MBS does not provide education and treatment recommendations to make it worthwhile.
- The SLP (seen outside of our clinic) will usually send for this.
- We go by patient report of symptoms.
- Taught in fellowship MBS not necessary since dysphagia is expected and results don't change management.
- If they report choking episodes associated with weight loss, we refer for a feeding tube.

training (22.6% of sites), and AAC therapy (6.5% of sites). A dietician was part of the healthcare team in 92.1% ($n = 35$) of ALS clinics surveyed.

Referral patterns for instrumental swallowing evaluation (Questions 9–11)

Figure 2 summarises response data for Question 9: 'What percentage of your patients do you refer for a modified barium swallow study?', and denotes the most common response as 'in less than 15% of patients' (51.4%, $n = 19$). Overall, 73% (27/37) of clinicians reported utilising the MBS examination in less than half (50%) of their patients (one missing data point). Reported criteria for MBS referral in those responding to Question 10 ($n = 32$) included: in all patients with suspected dysphagia and/or weight loss (47%, $n = 15$), in all ALS patients (6%, $n = 2$), and in bulbar-onset patients (3%, $n = 1$) and 44% ($n = 14$) of responding sites reported that they 'do not refer for MBS in any ALS patients' in question 10. Question 11 represented a follow-up question: 'What is the reason you do not perform an MBS evaluation?', yielding a total of 18 responses that are summarised below in Table 3.

Percutaneous gastrostomy tube placement (Questions 12–15)

Responses to Questions 12, 14 and 15 are provided in Figure 3. Responses to question 12 ('what percentage of your patients ultimately undergo PEG placement?') indicated that most respondents report '50–69% of patients', (36.8%, $n = 14$) with the '<15% of patients' representing the least chosen item selection (7.9%, $n = 3$). An equal number of responses for each of the remaining options (15–34%, 35–49% and >70%) was noted ($n = 7$ in




Figure 3. Percutaneous gastrostomy (PEG) tube patterns regarding the frequency (expressed as % patients seen) of placements (3A) and the influence of a patient's forced vital capacity (FVC) on clinical decision making (3B).

each, Figure 3a), indicating widespread responses for this particular question. When making feeding tube recommendations, 89.5% of clinicians surveyed reported that FVC was a factor in this clinical decision, with 47% recommending PEG placement in patients whose FVC is between 30% and 50% predicted; 44% recommending PEG placement when FVC is >50% predicted; and only 9% making this recommendation when FVC falls below 30% predicted (see Figure 3b). PEG tube procedures were most often performed by gastroenterologists (63.9%, $n=23$), followed by general surgeons (16.7%, $n=6$). Four clinicians (11.1%) reported that they refer to an outside facility for PEG placement while three clinicians selected the 'unknown' response option (8.3%).

Discussion

This survey includes a broad, demographic representation of clinical ALS research centres throughout the United States, including both university and non-university based centres. With 118 registered U.S. NEALS sites, our survey included 38 centres with one designated responder allowed per site. These responders included neurologists, nurse practitioners and speech language pathologists. The questions posed were limited in both scope and content for this initial study, focussing on practice patterns for the evaluation of bulbar function in ALS, thereby attempting to avoid excessive time demands for completion and enhancing overall survey participation.

Most of these sites offered SLP, AAC, and dietary professional health care services. Routinely collected bulbar clinical parameters varied in number and type, with the ALSFRS-R and body weight representing the only two parameters routinely collected in >90% of sites. Referral for instrumental swallowing examination (MBS) was noted to be significantly underutilised, with only 27% of sites routinely utilising this swallowing examination and 44% of clinical sites not utilising MBS in their practice. The relative percentage or number of ALS patients undergoing a PEG tube placement varied widely across sites. Although 90% of clinicians were in consensus that forced vital capacity (FVC) was a key consideration when making PEG placement recommendations, the specific FVC thresholds used in making this decision were not consistent across sites.

Clinical parameters routinely used in ALS clinics

Survey results highlighted consistent discrepancies involving routinely obtained clinical parameters across sites (Question 3, Figure 1). The selection of utilised clinical parameters from the available item list ranged from 1 to 8, from which no single outcome or test was routinely implemented across all (100%) of the clinical sites. The ALSFRS-R (18) represented the most commonly used outcome in 37/38 of the respondents. This finding was not surprising given that the ALSFRS-R represents one of the few validated scales for disease progression in ALS. This scale contains a 'bulbar subscale' with one question for each bulbar domain of speech, swallowing, and salivation. Realizing that this is a

patient self-report scale with recognised limitations including known floor and ceiling effects, the ALSFRS-R may represent an insensitive tool for the identification and tracking of bulbar function over time (19). Further, it has been noted that ALS patients tend to under-report swallowing impairment during the early stages of the disease due to progressive adaptation or compensation to subtle changes in swallowing function (20). Body weight (36/38) and FVC (34/38) were two other outcome measures collected by most sites, consistent with their recognised importance as markers of disease progression. BMI was routinely tracked in only 63% of sites ($n=24$) and a clinical swallowing evaluation ('clinical bedside') was reported in only 55% of sites ($n=21$).

Recognizing that dysphagia is reported to occur in up to 85% of ALS patients throughout the disease course, the finding that 45% of sites surveyed do not perform a basic clinical swallowing test raises the question of how dysphagia is currently being evaluated. Also of interest, objective speech testing represented the least utilised clinical parameter reported, with speaking rate and the sentence intelligibility test (SIT) routinely performed at only 18% ($n=7$) of sites. This may be clinically relevant given that recently published data identified speaking rate as a very sensitive marker and predictor of subsequent speech intelligibility decline (19,21–24). These tests have been designed to represent an easy to acquire and clinically useful outcome measure to longitudinally track ALS patients for optimal timing of augmentative communication devices before a significant reduction in communication abilities ultimately occurs. Evidence-based recommendations currently state that when speaking rate falls below 120 words per minute, referral for AAC services should be pursued, as rapid speech intelligibility decline occurs once this critical threshold has been reached (25–27).

Health care professionals and services offered

The majority of clinical sites utilised SLPs, dietitians and AAC experts within their clinics.

Instrumental swallowing examination referral patterns

Seventy-three percent of sites do not routinely refer for the MBS ($\leq 50\%$ patients) and the most common response option for Question 9 indicated that 19 sites (51% of sites) recommended the instrumental swallowing evaluation in less than 15% of their patients. Furthermore, in the follow-up question, 14 of 32 sites (44%) responded that they 'do not refer for MBS'. While the provided rationales for this clinical decision varied, several consistent themes emerged which included: (1) the belief that their clinical assessment alone was

sufficient; (2) the decision to make management recommendations based on patient report of symptoms; (3) the decision to immediately refer for PEG if choking with weight loss occurs; (4) the belief that MBS does not provide useful information, treatment recommendations or patient education opportunities; (5) physicians trained to believe that the MBS is not necessary since dysphagia is expected, and the results would not influence management; (6) risk of barium aspiration during the MBS; and (7) no access to MBS testing on-site. Given these survey results, we feel that further clarification on the utility of MBS in patients with ALS is warranted.

Clinical education in this area is important as it would highlight the role of instrumental assessment versus the potential limitations of less objective forms of clinical bulbar assessments to adequately and accurately determine dysphagia status. This may also help to address the following clinical concerns facing our bulbar patients, which include: (1) swallowing efficiency and safety impairments that cannot be directly visualised on the CSE; (2) the relatively high number of reports of 'silent' aspiration in ALS (28,29); (3) to determine the impact of specific swallowing treatments, compensations and dietary manipulations on swallowing function; and (4) to facilitate education to patients and caregivers of the impact of recommended treatments to help ensure compliance and maintenance of safe swallowing for the patient.

Percutaneous gastrostomy tube placement

No consistent patterns were revealed for question 12, 'what percentage of ALS patients ultimately undergo PEG placement', with even responses ($n=7$) across options of 15–34%, 35–49% and $>70\%$. The most commonly chosen option for this question indicated that 37% of sites ($n=14$) report that 50–69% of patients undergo PEG placement. These data may relate to different physician and patient preferences that are currently unclear. Gastroenterologists most often performed PEG placement, and although there was great variability regarding the number of PEGs placed, FVC was a consistently important consideration when referring for PEG. This may be directly related to the practice parameter update report by Miller et al. (2009), noting an increased risk of adverse events when FVC drops below 50%. It is therefore not surprising that only 9% responded that they would recommend a PEG if FVC dropped below 30%, but it is noteworthy that 47% of respondents would recommend a PEG if FVC fell between 30% and 50%.

Of significant clinical interest is the potential application of these survey results with practice patterns throughout the wider international ALS community. With regard to PEG placement, our survey questioned the percentage of patients undergoing this procedure, the methods of

placement and impact of FVC on this decision. Recent UK studies have focussed on the variability of gastrostomy practice patterns (30) and the large ProGas study, which assessed not only on the comparative methods of gastrostomy placement, but provided valuable clinical insight on the optimal timing of this procedure (31). Our findings compared similarly with ProGas results in terms of GI placement of the PEG, yet the total number of patients undergoing PEG in our study differed significantly across responding sites. The primary intent of this survey was to provide initial screening information on bulbar practice patterns, without specifically focussing on the overall management of bulbar disease. Future clinical studies incorporating international collaboration to identify universally accepted evaluation and management guidelines for our bulbar ALS patients are essential, and should be actively pursued.

This reported survey of current clinical bulbar practice patterns is limited by a relatively small number of sites responding ($n=38$) and the brief number of questions employed. Nevertheless, these findings have helped to establish initial bulbar practice pattern findings in ALS clinics geographically located throughout the U.S. This survey has also assisted in recognising several critical areas of concern, highlighting the need to establish an accepted consensus on bulbar assessment guidelines in order to advance the management and care of bulbar dysfunction in ALS.

A summary of the major points of concern raised from this survey would include: (1) a high degree of inconsistencies in clinical bulbar parameters routinely assessed in ALS clinics; (2) a preference for use of non-specific clinical tests and parameters to accurately track and monitor speech and swallowing function over time; (3) the underutilisation of both the clinical swallow evaluation and referral for instrumental swallowing examination; (4) physician education on the role of the MBS in both the assessment and treatment of dysphagia in ALS; (5) inclusion of speaking rate measurement as an aid to guide optimal timing of AAC interventions; and finally (6) the development of a validated, minimally invasive and efficient clinical assessment battery, sensitive enough to accurately track and monitor progressive bulbar decline, which could be routinely employed throughout all ALS clinics.

Declaration of interest

The authors declare no competing interests.

References

- Carpenter R, McDonald T, Howard F Jr. The otolaryngologic presentation of amyotrophic lateral sclerosis. *Otolaryngology*. 1977;86(3 Pt 1):ORL479–84.
- Chen A, Garrett CG. Otolaryngologic presentations of amyotrophic lateralsclerosis. *Otolaryngol Head Neck Surg*. 2005;132:500–4.
- Paris G, Martinaud O, Petit A, Cuvelier A, Hannequin D, Roppeneck P, et al. Oropharyngeal dysphagia in amyotrophic lateral sclerosis alters quality of life. *J Oral Rehabil*. 2013;40:199–204.
- Tabor L, Gaziano J, Watts S, Robison R, Plowman EK. Defining swallowing-related quality of life profiles in individuals with amyotrophic lateral sclerosis. *Dysphagia* 2016;31:376–82.
- Hecht M, Hillemacher T, Grasel E, Tigges S, Winterholler M, Heuss D, et al. Subjective experience and coping in ALS. *Amyotroph Lateral Scler Other Motor Neuron Disord*. 2002;3:225–31.
- Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. *Amyotroph Lateral Scler*. 2009;10:310–23.
- Kuhnlein P, Gdynia HJ, Sperfeld AD, Lindner-Pfleghar B, Ludolph AC, Prosiegel M, et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. *Nat Clin Pract Neurol*. 2008;4:366–74.
- Sorenson EJ, Crum B, Stevens JC. Incidence of aspiration pneumonia in ALS in Olmsted County, MN. *Amyotroph Lateral Scler*. 2007;8:87–9.
- Yang R, Huang R, Chen D, Song W, Zeng Y, Zhao B, et al. Causes and places of death of patients with amyotrophic lateral sclerosis in south-west China. *Amyotroph Lateral Scler*. 2011;12:206–9.
- Plowman EK, Tabor LC, Robison R, Gaziano J, Dion C, Watts SA, et al. Discriminant ability of the Eating Assessment Tool-10 to detect aspiration in individuals with amyotrophic lateral sclerosis. *Neurogastroenterol Motil*. 2016;28:85–90.
- Plowman EK, Watts SA, Robison R, Tabor L, Dion C, Gaziano J, et al. Voluntary cough airflow differentiates safe versus unsafe swallowing in amyotrophic lateral sclerosis. *Dysphagia*. 2016;3:383–90.
- Aridegbe T, Kandler R, Walters SJ, Walsh T, Shaw PJ, McDermott CJ. (The natural history of motor neuron disease: assessing the impact of specialist care. *Amyotroph Lateral Scler Frontotemporal Degener*. 2013;14:13–19.
- Chio A, Bottacchi E, Buffa C, Mutani R, Mora G. Paralysis: Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. *J Neurol Neurosurg Psychiatry*. 2006;77:948–50.
- Rooney J, Byrne S, Heverin M, Tobin K, Dick A, Donaghy C, et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. *J Neurol Neurosurg Psychiatry*. 2015;86:496–501.
- Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. *Arch Neurol*. 2000;57:1171–6.
- Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshe D, Johnston W, et al. Practice Parameter update: the care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2009;73:1227–33.
- Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. *Eur J Neurol*. 2012;19:360–75.
- Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, group BAs, Group AclotBS, et al. The

ALSFERS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. *J Neurol Sci.* 1999;169:13–21.

19. Green JR, Yunusova Y, Kuruvilla MS, Wang J, Pattee GL, Synhorst L, et al. Bulbar and speech motor assessment in ALS: challenges and future directions. *Amyotroph Lateral Sclerosis Frontotemp Degener.* 2013;14:494–500.
20. Solazzo A, Monaco L, Vecchio LD, Reginelli A, Iacobellis F, Capasso R, et al. Earliest videofluoromanometric pharyngeal signs of dysphagia in ALS patients. *Dysphagia.* 2014;29:539–44.
21. Mefferd AS, Green JR, Pattee G. A novel fixed-target task to determine articulatory speed constraints in persons with amyotrophic lateral sclerosis. *J Commun Disord.* 2012;45:35–45.
22. Rong P, Yunusova Y, Wang J, Green JR. Predicting early bulbar decline in amyotrophic lateral sclerosis: A speech subsystem approach. *Behav Neurol* 2015;2015:183027.
23. Simone M, Wilson EM, Yunusova Y, Green JR. Validation of clinical observations of mastication in persons with ALS. *Dysphagia.* 2016;3:367–75.
24. Yunusova Y, Green J, Lindstrom M, Ball L, Pattee G, Zinman L. Kinematics of disease progression in bulbar ALS. *J Commun Disord.* 2010;43:6.
25. Ball LJ, Beukelman DR, Pattee GL. Timing of speech deterioration in people with amyotrophic lateral sclerosis. *J Med Speech-Lang Pathol.* 2002;10:231–5.
26. Seiji NMN. Changes over time in dysarthric patients with amyotrophic lateral sclerosis (ALS): a study of changes in speaking rate and maximum repetition rate (MRR). *Clin Ling Phonet.* 2000;14:485–97.
27. Yorkston KM, Strand E, Miller R, Hillel A, Smith K. Speech deterioration in amyotrophic lateral sclerosis: implications for the timing of intervention. *J Med Speech-Lang Pathol.* 1993;1:35–46.
28. Ruoppolo G, Schettino I, Frasca V, Giacomelli E, Prosperini L, Cambieri C, et al. Dysphagia in amyotrophic lateral sclerosis: prevalence and clinical findings. *Acta Neurol Scand.* 2013;128:397–401.
29. Splaingard M, Hutchins B, Sulton L, Chaudhuri G. Aspiration in rehabilitation patients: videofluoroscopy vs bedside clinical assessment. *Arch Phys Med Rehabil.* 1988;69:637–40.
30. Stavroulakis T, Walsh T, Shaw P, McDermott C. Gastrostomy use in motor neurone disease (MND): a review, meta-analysis and survey of current practice. *Amyotroph Lateral Scler Frontotemporal Degener.* 2013;14:96–104.
31. ProGas Study Group. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. *Lancet Neurol.* 2015;14:702–9.

**Appendix
Survey Questions**

1. How many new and return ALS patients are seen in clinic each month?
 - <10%
 - 11–20
 - 21–30
 - 31–40
 - >40
2. What percentage of patients seen in the ALS clinic present with bulbar symptoms?
 - ≤15%

- 15–24
 - 25–34
 - 35–44
 - 45
3. Which of the following clinical parameters are routinely collected at each clinic visit (check all that apply).
 - ALSFERS-R
 - Weight
 - BMI
 - FVC
 - MIP
 - MEP
 - Speaking Rate
 - Sentence Intelligibility
 - Clinical Bedside Swallow Evaluation
 - Calorie Count
 4. Are there Speech-Language Pathology (SLP) services provided in your ALS clinic?
 - Yes/No
 5. How are SLPs utilised in the clinic?
 - See all ALS patients
 - Only ALS patients with bulbar symptoms
 - Per referral from the M.D. or other staff
 - Per patient/family request
 6. Is there a specific Augmentative and Alternative Communication (AAC) expert in your clinic?
 - Yes/No
 7. If yes, what services does this person provide?
 - AAC Evaluation
 - Communication Training
 - AAC Therapy
 8. Is there a dietician routinely utilised in the ALS clinic?
 - Yes/No
 9. What percentage of your patients do you refer for MBS?
 - <15%
 - 15–34
 - 35–49
 - 50–69
 - ≥70
 10. What is the criterion for referral for an MBS?
 - Every patient
 - All patients with suspected dysphagia and weight loss
 - All those with bulbar onset
 - We do not refer for MBS
 11. If you selected the last option above, what is the reason why you do not perform MBS evaluation?
 - Open Ended Answers. See Table 1.
 12. What percentage of ALS patients ultimately undergo PEG placement?
 - <15%
 - 15–34
 - 35–49
 - 50–69
 - ≥70
 13. By whom are PEG tubes routinely placed at your institution?
 - Gastroenterologist
 - Surgery
 - Outside Facility
 - Unknown
 14. Is FVC a factor in PEG placement?
 - Yes/No
 15. If yes, do you recommend PEG for ALS patients whose FVC:
 - Is >50%
 - Between 30–50%
 - Is <30%